How were Correvio Pharma's earnings last quarter?

Correvio Pharma Corp (NASDAQ:CORV) issued its quarterly earnings data on Monday, March, 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.06. The firm earned $11.33 million during the quarter, compared to the consensus estimate of $11.52 million. Correvio Pharma had a negative trailing twelve-month return on equity of 2,128.82% and a negative net margin of 107.81%.

What other stocks do shareholders of Correvio Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Correvio Pharma investors own include Inovio Pharmaceuticals (INO) , Outlook Therapeutics (OTLK) , SCYNEXIS (SCYX) , Heat Biologics (HTBX) , Actinium Pharmaceuticals (ATNM) , Acasti Pharma (ACST) , Biocept (BIOC) , Vaxart (VXRT) , Co-Diagnostics (CODX) .

NASDAQ:CORV

Correvio Pharma (CORV) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free CORV Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.42
▼
$0.42
50-Day Range: $0.39
▼
$0.42
52-Week Range: $0.21
▼
$2.79

Volume: N/A
Average Volume: 5.35 million shs
Market Capitalization: $27.80 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Correvio Pharma alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Correvio Pharma

Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

CORV Stock News Headlines

April 19, 2024 | wsj.com

Protect Pharmaceutical Corp.

April 16, 2024 | morningstar.com

Stella Pharma Corp Ordinary Shares 4888

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 9, 2024 | msn.com

Natco Pharma gets USFDA warning letter for Kothur plant

March 29, 2024 | markets.businessinsider.com

Hold Rating Maintained for Corvus Pharmaceuticals Amid Clinical Delays and Financing Concerns

March 19, 2024 | washingtonpost.com

Corvus: Q4 Earnings Snapshot

March 15, 2024 | bizjournals.com

'This is a sleeping giant:' UC seals licensing deal with TRPV Pharmaceuticals for new heart failure drug

March 13, 2024 | marketwatch.com

Corbus Pharmaceuticals Stock Climbs on Narrower-Than-Expected 4Q Loss

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 1, 2024 | msn.com

Garware Fulflex India acquires Avcor Health Care Products to strengthen its medical product portfolio

February 17, 2024 | wsj.com

Chong Kun Dang Pharmaceutical Corp.

February 12, 2024 | finance.yahoo.com

Silver Creek Pharmaceuticals Appoints Mark Corrigan, M.D. As President

January 14, 2024 | morningstar.com

Chong Kun Dang Pharmaceutical Corp

December 12, 2023 | seekingalpha.com

Corvus Pharmaceuticals: Ahead Of The Clinical-Stage Curve

December 7, 2023 | bizjournals.com

AbbVie is acquiring two local biotechs — but won't detail its plans for them

December 7, 2023 | msn.com

AbbVie – Cerevel M&A deal lifts Reviva, Karuna

November 30, 2023 | benzinga.com

Scout Clinical secures preferred supplier status with Top 5 Pharma Leader

November 27, 2023 | msn.com

Corvus Pharmaceuticals (CRVS) Price Target Increased by 10.92% to 8.03

November 22, 2023 | msn.com

AbbVie suing Sandoz, four others to block generic Rinvoq: report

November 16, 2023 | investing.com

Vietnam Pharmaceutical Corp (DVN)

November 16, 2023 | morningstar.com

Nymox Pharmaceutical Corp NYMXF

November 14, 2023 | morningstar.com

Nutra Pharma Corp NPHC

November 12, 2023 | msn.com

WHO Approves First African-Manufactured Malaria Drug

November 6, 2023 | morningstar.com

HPGC Renmintongtai Pharmaceutical Corp Class A 600829

October 30, 2023 | markets.businessinsider.com

Analyst Assessment On Reviva Pharmaceuticals' Positive Schizophrenia Trial Data - Sees More Than 200% Upside In Stock

September 29, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Maravai Lifesciences Holdings (MRVI), Johnson & Johnson (JNJ) and Amicus (FOLD)

September 15, 2023 | finance.yahoo.com

RAMM Pharma Corp. Announces Corporate Update

See More Headlines

Receive CORV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Correvio Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/30/2020
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CORV
CUSIP: N/A
CIK: N/A
Web: www.correvio.com
Phone: 604-677-6905
Fax: N/A
Employees: 133
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.79)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,180,000.00
Net Margins: -107.81%
Pretax Margin: N/A
Return on Equity: -2,128.82%
Return on Assets: -58.56%

Debt

Debt-to-Equity Ratio: 22.54
Current Ratio: 1.07
Quick Ratio: 0.95

Sales & Book Value

Annual Sales: $32.63 million
Price / Sales: 0.85
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.02) per share
Price / Book: -21.00

Miscellaneous

Outstanding Shares: 66,191,000
Free Float: N/A
Market Cap: $27.80 million
Optionable: Optionable
Beta: 0.08

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Mark H. N. Corrigan (Age 62)
CEO & Director
Mr. Justin A. Renz CPA (Age 48)
MST, M.S.T., MBA, CFO & Pres
Ms. Sheila M. Grant
Chief Operating Officer
Mr. David D. McMasters (Age 61)
Chief Compliance Officer & Gen. Counsel
Mr. Hugues Sachot
Chief Commercial Officer

Key Competitors

View All Competitors

CORV Stock Analysis - Frequently Asked Questions

How were Correvio Pharma's earnings last quarter?: Correvio Pharma Corp (NASDAQ:CORV) issued its quarterly earnings data on Monday, March, 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.06. The firm earned $11.33 million during the quarter, compared to the consensus estimate of $11.52 million. Correvio Pharma had a negative trailing twelve-month return on equity of 2,128.82% and a negative net margin of 107.81%.
What other stocks do shareholders of Correvio Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Correvio Pharma investors own include Inovio Pharmaceuticals (INO), Outlook Therapeutics (OTLK), SCYNEXIS (SCYX), Heat Biologics (HTBX), Actinium Pharmaceuticals (ATNM), Acasti Pharma (ACST), Biocept (BIOC), Vaxart (VXRT), Co-Diagnostics (CODX).

This page (NASDAQ:CORV) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Correvio Pharma (CORV) Stock Price, News & Analysis

About Correvio Pharma

CORV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CORV Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info